Edition:
India

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

15.28CNY
8:59am IST
Change (% chg)

¥0.30 (+2.00%)
Prev Close
¥14.98
Open
¥15.05
Day's High
¥15.48
Day's Low
¥14.92
Volume
8,064,284
Avg. Vol
8,956,493
52-wk High
¥16.70
52-wk Low
¥10.24

Latest Key Developments (Source: Significant Developments)

Zhejiang Hisun Pharmaceutical and unit obtain high-tech enterprise recognition and to enjoy tax preference
Thursday, 4 Jan 2018 

Jan 4(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it and unit were recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years .  Full Article

Zhejiang Hisun Pharmaceutical passes FDA approval
Tuesday, 21 Nov 2017 

Nov 21(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received approval for a kind of tablet from U.S Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical unit says product gets FDA approval
Monday, 20 Nov 2017 

Nov 20(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration.  Full Article

Zhejiang Hisun Pharmaceutical says product gets FDA approval
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says its product, mycophenolate mofetil capsules, gets approval from U.S. Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical says change of CFO
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says it appoints Liu Yuanyan as new CFO, replacing Guan Xuhua who resigns from the position due to internal change in job role.  Full Article

Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration .Certificate issued to crude drugs manufactured by the company and the valid period is until Nov. 26, 2020 .  Full Article

Zhejiang Hisun Pharmaceutical to invest 5.1 mln yuan to set up investment management JV
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:* Says it will invest 5.1 million yuan to set up Zhejiang-based investment management JV, which will be engaged in operation of pharmaceutical industry innovation projects, and hold 51 percent stake in JV after transaction .  Full Article

Celsion Co, Zhejiang Hisun Pharma sign deal for development of GEN-1 immuno-oncology therapy
Tuesday, 9 Aug 2016 

Celsion Corp : Co, Zhejiang Hisun Pharma sign technology transfer, manufacturing and commercial supply deal for development of GEN-1 immuno-oncology therapy . Hisun will collaborate with Celsion around regulatory approval activities for GEN-1 with CFDA . Agreement has targeted unit costs for clinical supplies of GEN-1 that are substantially competitive with company's current suppliers .Will provide Hisun a percentage certain of China's commercial unit demand, and separately of global commercial unit demand.  Full Article

Zhejiang Hisun Pharmaceutical unit gets GMP certificate
Monday, 25 Jul 2016 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>: Says its unit receives goods manufacture practice (GMP) certificate .Says certificate issued to the unit's imported drug packing production line and the valid period is until July 3, 2021.  Full Article

Zhejiang Hisun Pharmaceutical signs $3 mln technology transfer agreement with Nascent
Tuesday, 19 Jul 2016 

Zhejiang Hisun Pharmaceutical Co., Ltd. <600267.SS>:Says it signs $3 million technology transfer agreement with Nascent Biotech, Inc, to get exclusive right for Pritumumab, a targeted therapy for epithelioma.  Full Article

BRIEF-Zhejiang Hisun Pharmaceutical and unit obtain high-tech enterprise recognition and to enjoy tax preference

* Says it and unit were recognized as high-tech enterprise, and to enjoy a tax preference of 15 percent for three years